Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF.

Lung Cancer. 2019 Oct 3;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. [Epub ahead of print]

PMID:
31630043
2.

The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

Liem EI, Oddens JR, Vernooij R, Li R, Kamat AM, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM.

J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566. [Epub ahead of print]

PMID:
31549936
3.

Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon.

Haefliger S, Rebetez J, Buser PJ, Dirnhofer S, Bubendorf L.

Acta Cytol. 2019 Sep 17:1-5. doi: 10.1159/000502711. [Epub ahead of print]

PMID:
31527381
4.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I.

Arch Pathol Lab Med. 2019 Sep 11. doi: 10.5858/arpa.2019-0085-OA. [Epub ahead of print]

PMID:
31509456
5.

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P.

J Pathol. 2019 Aug 30. doi: 10.1002/path.5344. [Epub ahead of print]

PMID:
31471895
6.

The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH.

Vlajnic T, Gut A, Savic S, Bubendorf L.

J Clin Pathol. 2019 Aug 29. pii: jclinpath-2019-206109. doi: 10.1136/jclinpath-2019-206109. [Epub ahead of print]

PMID:
31467041
7.

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.

Dugas SG, Müller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW, Wyatt AW, Rentsch CA, Bubendorf L.

Cancer Cytopathol. 2019 Sep;127(9):578-585. doi: 10.1002/cncy.22167. Epub 2019 Aug 6.

PMID:
31386310
8.

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).

Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1099. doi: 10.3390/cancers11081099.

9.

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, Novelli G.

Cell Death Dis. 2019 Jul 11;10(7):534. doi: 10.1038/s41419-019-1770-3.

10.

PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.

Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L.

Virchows Arch. 2019 Jul;475(1):67-76. doi: 10.1007/s00428-019-02582-0. Epub 2019 May 24.

PMID:
31127385
11.

Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee.

Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Review.

PMID:
31050216
12.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
13.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
14.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK).

Br J Cancer. 2019 May;120(10):968-974. doi: 10.1038/s41416-019-0447-0. Epub 2019 Apr 16.

15.

Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.

Bausch K, Roth E, Heinz S, Horst D, Mathia S, Vlajnic T, Bubendorf L, Westhoff T, Wetterauer C, Seifert HH, Ebbing J.

PLoS One. 2019 Mar 14;14(3):e0213549. doi: 10.1371/journal.pone.0213549. eCollection 2019.

16.

Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 May;74(6):844-852. doi: 10.1111/his.13818. Epub 2019 Apr 1.

PMID:
30604878
17.

Compressed Sensing Radial Sampling MRI of Prostate Perfusion: Utility for Detection of Prostate Cancer.

Winkel DJ, Heye TJ, Benz MR, Glessgen CG, Wetterauer C, Bubendorf L, Block TK, Boll DT.

Radiology. 2019 Mar;290(3):702-708. doi: 10.1148/radiol.2018180556. Epub 2019 Jan 1.

PMID:
30599102
18.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
19.

Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.

Lorber T, Andor N, Dietsche T, Perrina V, Juskevicius D, Pereira K, Greer SU, Krause A, Müller DC, Savic Prince S, Lardinois D, Barrett MT, Ruiz C, Bubendorf L.

J Pathol. 2019 Feb;247(2):199-213. doi: 10.1002/path.5183. Epub 2018 Dec 28.

PMID:
30350422
20.

Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.

Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M.

PLoS One. 2018 Oct 15;13(10):e0205837. doi: 10.1371/journal.pone.0205837. eCollection 2018.

21.

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A.

J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.

22.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

PMID:
30206164
23.

Predictive potential and need for standardization of PD-L1 immunohistochemistry.

Savic Prince S, Bubendorf L.

Virchows Arch. 2019 Apr;474(4):475-484. doi: 10.1007/s00428-018-2445-7. Epub 2018 Sep 1.

PMID:
30173280
24.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
25.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.

26.

Protocols for Tissue Microarrays in Prostate Cancer Studies.

Vlajnic T, Eppenberger-Castori S, Bubendorf L.

Methods Mol Biol. 2018;1786:103-116. doi: 10.1007/978-1-4939-7845-8_6.

PMID:
29786789
27.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2.

PMID:
29717265
28.

Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability.

Viganó C, von Schubert C, Ahrné E, Schmidt A, Lorber T, Bubendorf L, De Vetter JRF, Zaman GJR, Storchova Z, Nigg EA.

Mol Biol Cell. 2018 May 1;29(9):1031-1047. doi: 10.1091/mbc.E17-10-0577.

29.

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.

Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, Ruiz C.

J Pathol. 2018 May;245(1):74-84. doi: 10.1002/path.5052. Epub 2018 Apr 2.

PMID:
29484655
30.

Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.

Vlajnic T, Savic S, Barascud A, Baschiera B, Bihl M, Grilli B, Herzog M, Rebetez J, Bubendorf L.

Cancer Cytopathol. 2018 Jun;126(6):421-429. doi: 10.1002/cncy.21983. Epub 2018 Feb 16.

31.

Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study.

Diebold M, Soltermann A, Hottinger S, Haile SR, Bubendorf L, Komminoth P, Jochum W, Grobholz R, Theegarten D, Berezowska S, Darwiche K, Oezkan F, Kohler M, Franzen DP.

Respir Res. 2017 Dec 16;18(1):210. doi: 10.1186/s12931-017-0693-8.

32.

Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus.

Müller DC, Rämö M, Naegele K, Ribi S, Wetterauer C, Perrina V, Quagliata L, Vlajnic T, Ruiz C, Balitzki B, Grobholz R, Gosert R, Ajuh ET, Hirsch HH, Bubendorf L, Rentsch CA.

J Pathol. 2018 Mar;244(3):265-270. doi: 10.1002/path.5012. Epub 2018 Feb 1.

PMID:
29205775
33.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

34.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

PMID:
29186353
35.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

36.

Alveolar herniation in transbronchial lung biopsy: a newly recognised diagnostic pitfall.

Jain D, Tamm M, Savic S, Bubendorf L.

Histopathology. 2018 Mar;72(4):710-712. doi: 10.1111/his.13411. Epub 2017 Dec 4. No abstract available.

PMID:
28986988
37.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA; Lungscape Consortium.

Lung Cancer. 2017 Sep;111:143-149. doi: 10.1016/j.lungcan.2017.07.021. Epub 2017 Jul 22.

PMID:
28838386
38.

[The Paris system for classification of urinary cytology].

Savic S, Vlajnic T, Bubendorf L.

Pathologe. 2017 Sep;38(5):451-462. doi: 10.1007/s00292-017-0325-6. German.

PMID:
28791453
39.

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?

Rentsch CA, Müller DC, Ruiz C, Bubendorf L.

Eur Urol. 2017 Dec;72(6):960-961. doi: 10.1016/j.eururo.2017.06.022. Epub 2017 Jul 5. No abstract available.

PMID:
28688612
40.

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E.

Eur Respir Rev. 2017 Jun 28;26(144). pii: 170007. doi: 10.1183/16000617.0007-2017. Print 2017 Jun 30. Review.

41.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

42.

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A.

Virchows Arch. 2017 Jul;471(1):49-55. doi: 10.1007/s00428-017-2131-1. Epub 2017 May 20.

PMID:
28528511
43.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

44.

Lonely Driver ROS1.

Savic S, Rothschild S, Bubendorf L.

J Thorac Oncol. 2017 May;12(5):776-777. doi: 10.1016/j.jtho.2017.02.019. No abstract available.

45.

[The pathology of adverse events with immune checkpoint inhibitors].

Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD.

Pathologe. 2017 May;38(3):197-208. doi: 10.1007/s00292-017-0281-1. Review. German.

PMID:
28421272
46.

Unexpected Intracameral Foreign Body during Routine Cataract Surgery.

Eggenschwiler L, Savic Prince S, Bubendorf L, Walder C, Goldblum D.

Klin Monbl Augenheilkd. 2017 Apr;234(4):436-438. doi: 10.1055/s-0042-119567. Epub 2017 Mar 22. No abstract available.

PMID:
28329885
47.

Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma.

Butt E, Ebbing J, Bubendorf L, Ardelt P.

Biomark Med. 2017 Apr;11(4):347-357. doi: 10.2217/bmm-2016-0348. Epub 2017 Mar 14.

PMID:
28290211
48.

T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance.

Dasen B, Vlajnic T, Mengus C, Ruiz C, Bubendorf L, Spagnoli G, Wyler S, Erne P, Resink TJ, Philippova M.

J Pathol Clin Res. 2016 Nov 26;3(1):44-57. doi: 10.1002/cjp2.61. eCollection 2017 Jan.

49.

Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer.

Berezowska S, Galván JA, Langer R, Bubendorf L, Savic S, Gugger M, Schmid RA, Marti TM.

Virchows Arch. 2017 Mar;470(3):323-330. doi: 10.1007/s00428-016-2057-z. Epub 2017 Jan 7.

PMID:
28062918
50.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

Supplemental Content

Loading ...
Support Center